SLC5A2 and type 2 diabetes mellitus: In order to better understand how SGLT2 inhibitors and incretin-based therapies influence diastolic function in T2DM, while elucidating the mechanisms involved, continued preclinical studies utilizing both pharmacological and mouse genetics approaches are necessary.